Catalyst
Head-to-head obesity data against Lilly's tirzepatide will reshape GLP-1 competitive dynamics.
Date
September 30, 2026
Phase
Phase III
Status
upcoming
Signal score
9.6
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.